These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 16771948)

  • 21. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
    Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM
    Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response.
    Kamal SM; El Kamary SS; Shardell MD; Hashem M; Ahmed IN; Muhammadi M; Sayed K; Moustafa A; Hakem SA; Ibrahiem A; Moniem M; Mansour H; Abdelaziz M
    Hepatology; 2007 Dec; 46(6):1732-40. PubMed ID: 17943989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Higher doses of peginterferon alpha-2b administered twice weekly improve sustained virological response in difficult-to-treat patients with chronic hepatitis C: results of a pilot randomized study.
    Lodato F; Azzaroli F; Brillanti S; Colecchia A; Tamé MR; Montagnani M; Muratori R; Giovanelli S; Feletti V; Bacchi Reggiani ML; Roda E; Mazzella G
    J Viral Hepat; 2005 Sep; 12(5):536-42. PubMed ID: 16108771
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.
    Mangia A; Ricci GL; Persico M; Minerva N; Carretta V; Bacca D; Cela M; Piattelli M; Annese M; Maio G; Conte D; Guadagnino V; Pazienza V; Festi D; Spirito F; Andriulli A
    J Viral Hepat; 2005 May; 12(3):292-9. PubMed ID: 15850470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
    Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
    J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The effect of patient's body weight, gender and baseline viral load on the efficacy of hepatitis C therapy].
    Husa P; Slesinger P; Stroblová H; Svobodník A
    Vnitr Lek; 2006 Jun; 52(6):590-5. PubMed ID: 16871762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of genotype 1b HCV-related chronic hepatitis: efficacy and toxicity of three different interferon alfa-2b/ribavirin combined regimens in naive patients.
    Scotto G; Fazio V; Palumbo E; Cibelli DC; Saracino A; Angarano G
    New Microbiol; 2005 Jan; 28(1):23-9. PubMed ID: 15782623
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial.
    Bruno S; Cammà C; Di Marco V; Rumi M; Vinci M; Camozzi M; Rebucci C; Di Bona D; Colombo M; Craxì A; Mondelli MU; Pinzello G
    J Hepatol; 2004 Sep; 41(3):474-81. PubMed ID: 15336451
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone.
    Min AD; Jones JL; Esposito S; Lebovics E; Jacobson IM; Klion FM; Goldman IS; Geders JM; Tobias H; Bodian C; Bodenheimer HC
    Am J Gastroenterol; 2001 Apr; 96(4):1143-9. PubMed ID: 11316161
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment effects and predictors of a 24-week course of interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C.
    Tomimatsu M; Aizawa Y; Chuganji Y; Ishizuka H; Fujita Y; Aizawa R; Abe H; Matsuda T; Itou Y; Nakanishi H; Ushiyama H; Higuchi T; Fujimoto T; Endou H; Iga D; Ohta K; Kuroda H
    J Gastroenterol Hepatol; 2006 Jul; 21(7):1177-83. PubMed ID: 16824072
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical trial: a randomized trial of pegylated-interferon-alpha-2a plus ribavirin with or without amantadine in treatment-naïve or relapsing chronic hepatitis C patients.
    Langlet P; D'Heygere F; Henrion J; Adler M; Delwaide J; Van Vlierberghe H; Mulkay JP; Lasser L; Brenard R; Horsmans Y; Michielsen P; Laureys A; Nevens F
    Aliment Pharmacol Ther; 2009 Aug; 30(4):352-63. PubMed ID: 19485978
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Taste disturbances during therapy with pegylated interferon-alpha 2b and ribavirin in patients with chronic hepatitis C.
    Klimacka-Nawrot E; Musialik J; Suchecka W; Petelenz M; Hartman M; Lichtański P; Błońska-Fajfrowska B
    Wiad Lek; 2010; 63(4):289-99. PubMed ID: 21608370
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus.
    Hashimoto Y; Kanto H; Itoh M
    J Dermatol; 2007 Aug; 34(8):577-82. PubMed ID: 17683392
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful treatment of resistant chronic hepatitis C virus infection with high dose pegylated interferon.
    Khokhar N; Butt MB; Gill ML
    J Coll Physicians Surg Pak; 2005 Jan; 15(1):41-2. PubMed ID: 15670525
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Current trends and first clinical studies of therapy for chronic hepatitis C in children using pegylated interferon alpha and ribavirin].
    Słuzewski W; Mozer-Lisewska I; Figlerowicz M; Kowala-Piaskowska A; Słuzewska M
    Przegl Epidemiol; 2005; 59(2):595-9. PubMed ID: 16190571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interstitial pneumonitis after combination therapy with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C.
    Chen YC; Lu SN; Lin MC
    Chang Gung Med J; 2007; 30(1):92-7. PubMed ID: 17477035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety, efficacy and pharmacokinetics of peginterferon alpha2a (40 kd) in children with chronic hepatitis C.
    Schwarz KB; Mohan P; Narkewicz MR; Molleston JP; Nash SR; Hu S; Wang K; Gries JM
    J Pediatr Gastroenterol Nutr; 2006 Oct; 43(4):499-505. PubMed ID: 17033526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of chronic hepatitis C patients with combination of alpha-interferon and ribavirin, consensus and pegylated interferons.
    Husa P; Husova L
    Bratisl Lek Listy; 2001; 102(5):248-52. PubMed ID: 11725377
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peginterferon alfa-2b plus ribavirin for chronic hepatitis.
    Santin M; Shaw E
    Lancet; 2002 Jan; 359(9302):263; author reply 264. PubMed ID: 11812596
    [No Abstract]   [Full Text] [Related]  

  • 40. Recent i.v.-drug users with chronic hepatitis C can be efficiently treated with daily high dose induction therapy using consensus interferon: an open-label pilot study.
    Witthoeft T; Fuchs M; Ludwig D
    World J Gastroenterol; 2007 Jan; 13(4):579-84. PubMed ID: 17278224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.